Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2025 Earnings Call Transcript
Operator: Welcome to Crinetics Pharmaceuticals Second Quarter 2025 Financial Results Conference Call.
Crinetics Pharmaceuticals Inc. (CRNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 6,400,025 | $184,064,719 | +3% | 1.47% |
| 2. | Farallon Capital Thomas Steyer | 4,646,098 | $133,621,778 | +1% | 0.58% |
| 3. | EcoR1 Capital Oleg Nodelman | 4,288,120 | $123,326,331 | 7.3% | |
| 4. | Point72 Asset Management Steve Cohen | 1,998,161 | $57,467,104 | +157% | 0.11% |
| 5. | Siren L.L.C. Raymond Debbane | 1,688,611 | $48,564,452 | 2.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.06 | 5,000 | $110,300.00 | 5,000 | 2023-06-08 | Filing | |
| $22.22 | 157,515 | $3,499,983.30 | 5,321,032 | 2022-04-18 | Filing | |
| $19.80 | 1,200,000 | $23,760,000.00 | 5,163,517 | 2021-10-25 | Filing | |
| $16.44 | 304,136 | $4,999,995.84 | 3,963,517 | 2021-04-08 | Filing | |
| $13.10 | 4,000 | $52,400.00 | 4,000 | 2020-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.23 | 97,483 | $3,141,877.09 | 99,713 | 2025-06-12 | Filing | |
| $34.83 | 127 | $4,423.41 | 72,233 | 2025-03-19 | Filing | |
| $34.17 | 2,388 | $81,597.96 | 72,360 | 2025-03-19 | Filing | |
| $34.83 | 361 | $12,573.63 | 87,491 | 2025-03-19 | Filing | |
| $34.17 | 6,801 | $232,390.17 | 87,852 | 2025-03-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,125,999 | $406,263,730 | 0.02% | |
| 2. | 9,256,132 | $266,206,356 | 0% | |
| 3. | 7,418,715 | $213,362,244 | 0% | |
| 4. | 5,807,308 | $167,018,179 | 0.03% | |
| 5. | 3,410,320 | $98,063,217 | 0.05% |
News See All
Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data
Crinetics Pharmaceuticals, Inc.
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Should You Hold Crinetics Pharmaceuticals (CRNX)?
PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript May 8, 2025Crinetics Pharmaceuticals, Inc. misses on earnings expectations.
11 Stocks That Will Bounce Back According to Analysts
Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone. Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call.
10 Worst Performing Mid Cap Stocks to Buy According to Analysts
Market analysts are increasingly highlighting mid-cap stocks as a potentially attractive investment opportunity, particularly in the current economic climate.
15 Stocks That Took a Nosedive in January
Historically, the S&P 500's performance in January sets the pace for the rest of the year.
Billionaire Hedge Funds
